Baxter International Inc. $BAX Shares Acquired by Gamco Investors INC. ET AL

Posted by Geri Gentry on May 20th, 2026

Gamco Investors INC. ET AL increased its position in Baxter International Inc. (NYSE:BAX – Free Report) by 9.9% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 391,250 shares of the medical instruments supplier’s stock after purchasing an additional 35,300 shares during the period. Gamco Investors INC. ET AL’s holdings in Baxter International were worth $7,477,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Cooke & Bieler LP raised its holdings in shares of Baxter International by 25.7% during the third quarter. Cooke & Bieler LP now owns 2,200,860 shares of the medical instruments supplier’s stock valued at $50,114,000 after buying an additional 450,350 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Baxter International by 32.4% during the third quarter. Russell Investments Group Ltd. now owns 2,515,928 shares of the medical instruments supplier’s stock worth $57,243,000 after purchasing an additional 615,100 shares in the last quarter. Greenhaven Associates Inc. bought a new stake in Baxter International during the third quarter worth approximately $143,186,000. DNB Asset Management AS increased its holdings in shares of Baxter International by 304.7% in the third quarter. DNB Asset Management AS now owns 398,118 shares of the medical instruments supplier’s stock valued at $9,065,000 after buying an additional 299,750 shares in the last quarter. Finally, Stoneridge Investment Partners LLC bought a new position in shares of Baxter International in the third quarter valued at $2,128,000. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Baxter International Stock Performance

NYSE BAX opened at $18.34 on Wednesday. The firm has a market cap of $9.47 billion, a price-to-earnings ratio of -8.61, a PEG ratio of 2.86 and a beta of 0.62. The company has a 50 day moving average of $17.40 and a 200-day moving average of $18.72. The company has a current ratio of 1.85, a quick ratio of 1.23 and a debt-to-equity ratio of 1.43. Baxter International Inc. has a 1-year low of $15.73 and a 1-year high of $32.04.

Baxter International (NYSE:BAX – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.36 EPS for the quarter, beating the consensus estimate of $0.31 by $0.05. Baxter International had a negative net margin of 9.70% and a positive return on equity of 16.15%. The business had revenue of $2.70 billion for the quarter, compared to analysts’ expectations of $2.62 billion. During the same period in the prior year, the firm earned $0.62 earnings per share. Baxter International’s revenue was up 2.9% compared to the same quarter last year. On average, equities analysts forecast that Baxter International Inc. will post 1.92 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Friday, May 29th will be issued a $0.01 dividend. The ex-dividend date is Friday, May 29th. This represents a $0.04 annualized dividend and a yield of 0.2%. Baxter International’s dividend payout ratio (DPR) is -1.88%.

Analysts Set New Price Targets

Several research firms have weighed in on BAX. Citigroup lowered their price objective on shares of Baxter International from $21.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 11th. Wall Street Zen cut shares of Baxter International from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Jefferies Financial Group decreased their price objective on shares of Baxter International from $21.00 to $19.00 and set a “hold” rating for the company in a report on Friday, February 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Baxter International in a report on Friday. Finally, The Goldman Sachs Group boosted their target price on shares of Baxter International from $17.00 to $19.00 in a research report on Friday, May 1st. Two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus target price of $19.91.

Read Our Latest Stock Analysis on BAX

Baxter International Profile

(Free Report)

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.